Lucitanib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as an inhibitor of fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptors (VEGFR), which are critical in tumor growth and angiogenesis. By blocking these receptors, Lucitanib helps to impede the blood supply to tumors, thereby inhibiting their growth and spread. It is particularly explored in the treatment of advanced solid tumors, including breast cancer and non-small cell lung cancer, especially in cases where these cancers exhibit alterations in FGFR pathways. Clinical trials continue to assess its efficacy and safety in various cancer types, aiming to provide a therapeutic option for patients with limited treatment alternatives.